Phenylimidazolidin-2-one Derivatives as Selective 5-HT<sub>3</sub> Receptor Antagonists and Refinement of the Pharmacophore Model for 5-HT<sub>3</sub> Receptor Binding
作者:Franco Heidempergher、Antonio Pillan、Vittorio Pinciroli、Fabrizio Vaghi、Claudio Arrigoni、Giorgio Bolis、Carla Caccia、Luciano Dho、Robert McArthur、Mario Varasi
DOI:10.1021/jm970060o
日期:1997.10.1
metoclopramide, a D2 receptor antagonist with weak 5-HT3 receptor antagonist properties, and zetidoline, a D2 receptor antagonist. Starting from this premise, a series of phenylimidazolidin-2-one derivatives bearing a basic azabicycloalkyl or an imidazolylalkyl moiety were synthesized and evaluated for 5-HT3 receptor radioligand binding affinity ([3H]-GR 43,694). In vitro 5-HT3 receptor antagonist activity was
根据甲氧氯普胺(一种具有弱的5-HT3受体拮抗剂特性的D2受体拮抗剂)与zeetidoline的相似性,提出了苯甲酰胺基与苯基咪唑啉酮-2-酮部分之间可能存在的生物等排体, D2受体拮抗剂。从这个前提出发,合成了一系列带有碱性氮杂双环烷基或咪唑基烷基部分的苯基咪唑啉二-2-酮衍生物,并评估了其与5-HT3受体放射性配体的结合亲和力([3H] -GR 43,694)。在豚鼠回肠分析(GPI)中测试了体外5-HT3受体拮抗剂的活性。通过抑制麻醉大鼠的Bezold-Jarisch反射确定了许多高亲和力配体是体内有效的5-HT3受体拮抗剂。一般来说,发现咪唑基烷基衍生物比氮杂双环烷基更具活性。1-(3,5-二氯苯基)-3-[(5-甲基-1H-咪唑-4-基)甲基]咪唑啉丁-2-酮(58)特别显示出对5-HT3的极高亲和力在GPI分析中,其Kb为5.62 nM(Ki为0.038 nM),比测试的参比化